Data on 15 patients mobilized with melphalan (60 mg/m2) and G-CSF
Age, y (range) | 58 (33-73) |
| Sex | 8 men, 7 women |
| Myeloma protein | |
| IgG | κ = 3, λ = 3 |
| IgA | κ = 3, λ = 3 |
| Light chain only | κ = 1, λ = 1 |
| Nonsecretory | κ = 1 |
| Stage of disease, no. of patients | |
| II | 7 |
| III | 7 |
| Plasma cell leukemia | 1 |
| Days from melphalan to first collection (range) | 19 (13-22) |
| No. of leukaphereses (range) | 2 (1-5) |
| Total CD34+ cells collected × 106/kg (range) | 14.1 (3.5-40.0) |
| CD34+ cells × 106/kg infused for SCT (range) | 6.8 (3.1-10.7) |
| Days from SCT to ANC more than 0.5 × 109/L (range) | 9 (8-11) |
| Days from SCT to platelets more than 20 × 109/L untransfused (range) | 12 (10-16) |
| CD34+ cells in 13 paired—day 1, day 2—collections | |
| Day 1, % | 1.6 ± 1.4 |
| Day 1, no. × 106/kg | 3.2 ± 2.9 |
| Day 2, % | 1.9 ± 1.3 |
| Day 2, no. × 106/kg | 6.8 ± 5.6 |
| Day 1 vs day 2, paired t test, % | P = .11 |
| Day 1 vs day 2, paired t test, no. | P < .01 |
| Clonotypic cells* in 13 paired—day 1, day 2—collections | |
| Day 1, % | 0.009 ± 0.013 |
| Day 1, no. × 104/kg | 1.9 ± 2.7 |
| Day 2, % | 0.016 ± 0.033 |
| Day 2, no. × 104/kg | 4.0 ± 7.7 |
| Day 1 vs day 2, paired t test, % | P = .44 |
| Day 1 vs day 2, paired t test, no. | P = .37 |
| Clonotypic cells,* 29 collections; median (range) % | 0.0009 (0-0.1) |
| No. × 104/kg | 0.5 (0-41.2) |
Age, y (range) | 58 (33-73) |
| Sex | 8 men, 7 women |
| Myeloma protein | |
| IgG | κ = 3, λ = 3 |
| IgA | κ = 3, λ = 3 |
| Light chain only | κ = 1, λ = 1 |
| Nonsecretory | κ = 1 |
| Stage of disease, no. of patients | |
| II | 7 |
| III | 7 |
| Plasma cell leukemia | 1 |
| Days from melphalan to first collection (range) | 19 (13-22) |
| No. of leukaphereses (range) | 2 (1-5) |
| Total CD34+ cells collected × 106/kg (range) | 14.1 (3.5-40.0) |
| CD34+ cells × 106/kg infused for SCT (range) | 6.8 (3.1-10.7) |
| Days from SCT to ANC more than 0.5 × 109/L (range) | 9 (8-11) |
| Days from SCT to platelets more than 20 × 109/L untransfused (range) | 12 (10-16) |
| CD34+ cells in 13 paired—day 1, day 2—collections | |
| Day 1, % | 1.6 ± 1.4 |
| Day 1, no. × 106/kg | 3.2 ± 2.9 |
| Day 2, % | 1.9 ± 1.3 |
| Day 2, no. × 106/kg | 6.8 ± 5.6 |
| Day 1 vs day 2, paired t test, % | P = .11 |
| Day 1 vs day 2, paired t test, no. | P < .01 |
| Clonotypic cells* in 13 paired—day 1, day 2—collections | |
| Day 1, % | 0.009 ± 0.013 |
| Day 1, no. × 104/kg | 1.9 ± 2.7 |
| Day 2, % | 0.016 ± 0.033 |
| Day 2, no. × 104/kg | 4.0 ± 7.7 |
| Day 1 vs day 2, paired t test, % | P = .44 |
| Day 1 vs day 2, paired t test, no. | P = .37 |
| Clonotypic cells,* 29 collections; median (range) % | 0.0009 (0-0.1) |
| No. × 104/kg | 0.5 (0-41.2) |
ANC indicates absolute neutrophil count.
All 15 patients had stem cell collections on day 1; 13 had collections on day 2, and 1 had a third collection on day 3, giving a total of 29 collections, CD34 and clonotypic contamination data for the 13 paired collections (means ± SD) and clonotypic data for all 29 collections are shown. To compute estimates of contamination, the higher percentage obtained with VL or VH PCR was used.